130 related articles for article (PubMed ID: 16914576)
1. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Meek K; Goodwin A; Goodspeed W; Kromplewski M; Fouts ME; Medina D; Cho SY; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2006 Aug; 12(16):4882-7. PubMed ID: 16914576
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Hande KR; Hagey A; Berlin J; Cai Y; Meek K; Kobayashi H; Lockhart AC; Medina D; Sosman J; Gordon GB; Rothenberg ML
Clin Cancer Res; 2006 May; 12(9):2834-40. PubMed ID: 16675578
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
Widemann BC; Goodspeed W; Goodwin A; Fojo T; Balis FM; Fox E
J Clin Oncol; 2009 Feb; 27(4):550-6. PubMed ID: 19075272
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Yee KW; Hagey A; Verstovsek S; Cortes J; Garcia-Manero G; O'Brien SM; Faderl S; Thomas D; Wierda W; Kornblau S; Ferrajoli A; Albitar M; McKeegan E; Grimm DR; Mueller T; Holley-Shanks RR; Sahelijo L; Gordon GB; Kantarjian HM; Giles FJ
Clin Cancer Res; 2005 Sep; 11(18):6615-24. PubMed ID: 16166440
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
10. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI; Fox E; Turpin BK; Goldstein SL; Liu X; Minard CG; Kudgus RA; Reid JM; Berg SL; Weigel BJ
Cancer; 2018 Dec; 124(23):4548-4555. PubMed ID: 30394521
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
14. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
Mossé YP; Lipsitz E; Fox E; Teachey DT; Maris JM; Weigel B; Adamson PC; Ingle MA; Ahern CH; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6058-64. PubMed ID: 22988055
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
[TBL] [Abstract][Full Text] [Related]
16. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
Fox E; Mosse' YP; Meany HM; Gurney JG; Khanna G; Jackson HA; Gordon G; Shusterman S; Park JR; Cohn SL; Adamson PC; London WB; Maris JM; Balis FM
Pediatr Blood Cancer; 2014 Jun; 61(6):990-6. PubMed ID: 24347462
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
